A phase 1b study of cetuximab and BYL719 (Alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
LA Dunn, N Riaz, MG Fury, SM McBride… - International Journal of …, 2020 - Elsevier
Purpose Activation of the PI3K/mTOR signaling pathway is common in head and neck
squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic
and efficacious when combined with cetuximab, a Food and Drug Administration–approved
radiosensitizing agent in the treatment of HNSCC. The agent independently has been
shown to enhance radiosensitivity. This study evaluates the addition of BYL719 to cetuximab
and radiation in the treatment of locally advanced HNSCC. Methods and Materials This is a …
squamous cell carcinoma (HNSCC). BYL719 is an α-specific PI3K inhibitor that is synergistic
and efficacious when combined with cetuximab, a Food and Drug Administration–approved
radiosensitizing agent in the treatment of HNSCC. The agent independently has been
shown to enhance radiosensitivity. This study evaluates the addition of BYL719 to cetuximab
and radiation in the treatment of locally advanced HNSCC. Methods and Materials This is a …